Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy